News Pharming Group N.V. Nasdaq

Equities

PHAR

US71716E1055

Delayed Nasdaq Other stock markets 09:34:29 20/06/2024 pm IST			5-day change	1st Jan Change
8.245 ^USD	-3.54%		-4.09%	-27.87%

31/05	Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug	MT
30/05	Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Pharming N : Jefferies Healthcare Conference Presentation June 5 6, 2024	05/06	PU
Pharming Group to participate in June investor conferences	03/06	GL
Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug	31/05	MT
Pharming N : Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union - Form 6-K	31/05	PU
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union	31/05	GL
Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union	31/05	CI
Pharming N : Physical Settlement Notice 2029 Convertible Bonds	28/05	PU
Pharming N : Publication of Voting Results of the AGM 2024	23/05	PU
Pharming N : Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders	22/05	PU
Pharming N : Presentation AGM 2024	21/05	PU
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders	21/05	GL
Transcript : Pharming Group N.V. - Shareholder/Analyst Call	21/05
Pharming Group to participate in May investor conference	20/05	GL
Pharming N : Presentatie - mei 2024	16/05	PU
Pharming N : Corporate Presentation - May 2024	15/05	PU
Pharming N : 1Q 2024 financial results - Analyst & Investor Call transcript	15/05	PU
Pharming N : Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025	15/05	PU
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025	15/05	GL
Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024	08/05
Pharming N : 1Q 2024 Financial Results Presentation - May 8, 2024	08/05	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pharming Group N.V. Nasdaq

Equities

PHAR

US71716E1055

Summary

Filters